Abstract
Introduction 48
Alpha-1-antitrypsin (A1AT) deficiency is one of the most common metabolic-genetic 49 liver diseases (22) . It occurs in 1 in 2,000-3,500 births in Caucasian populations, and is 50 associated with chronic liver disease, cirrhosis and hepatocellular carcinoma in children 51 and adults. The Z mutant allele of the A1AT gene (SERPINA1) is a point mutation that 52 encodes a single amino acid substitution. This mutation is associated with the vast 53 majority of A1AT liver disease as the classical form of homozygous, ZZ A1AT 54 deficiency. In the liver, large quantities of A1AT protein are synthesized, and rapidly 55 secreted in the case of the WT A1AT protein. However, the A1AT mutant Z protein folds 56 inefficiently during biogenesis and only 15% of the mutant Z molecules are secreted by 57 the usual pathways while 85% are retained in the ER by quality control mechanisms (20, 58 22) . Most of the mutant Z molecules retained are degraded by ER-associated degradation 59 (ERAD) (14, 20, 22) . Some of the A1AT mutant Z molecules polymerize into a complex 60 quaternary structure and can accumulate in the "globules" of dilated ER known to be the 61 classical hepatic lesion in this disease. Our laboratory was the first to show that 62 autophagy was a pathway for degradation of the A1AT mutant Z polymers and that AAT 63 mutant Z protein was present within autophagosomes (23). The mechanism of the liver 64 injury results directly from the accumulation within hepatocytes of the A1AT mutant Z 65 protein (1, 11, 22) . This accumulation is heterogeneous among hepatocytes and in the 66 cells with the largest mutant Z protein burden, the accumulation triggers hepatocellular 67 death. The death process is a cascade involving apoptosis, redox injury and mitochondrial 68 injury, followed by compensatory regeneration and, in some patients, hepatic fibrosis and 69 HCC result. 70
METHODS 96 Animals 97
Instructions in (NIH, "Guide for Care and Use of Laboratory Animals" were 98 followed, as previously described(12) . Protocols were approved by the animal studies 99 committees of St. Louis University. Mice were housed with 12h dark-light cycles and 100 food + water ad libitum in a barrier facility. PiZ mice, described previously, were 101 maintained on a C57Bl/6 background. NorUDCA in a dose of 425mg/kg/d was given 102 orally in chow for periods of up to 6 weeks (age 3 weeks to 9 weeks), with standard chow 103 as vehicle. 3 groups of 10 PiZ mice and one group of 10 WT, C57Bl/6 mice were given 104 norUDCA and compared to equal groups of litter mate matched mice given control 105 vehicle only. Additional groups of 5 mice were analyzed for dose-response to norUDCA. 106 PiZ mice are transgenic for the human A1AT mutant Z gene and express hepatic and 107 serum levels of human A1AT protein similar to homozygous ZZ humans. The 108 endogenous murine anti-protease genes are intact, but are significantly different from 109 human A1AT and are immunologically distinguishable, as previously published (1, 3, 9) . 110 111
Liver Analysis 112
Sacrifice of the mice, liver sectioning, staining and examination was carried out as 113 previously described (11, 12) . BrdU labeling using 72h osmotic pumps prior to sacrifice 114 in the PiZ mice and subsequent staining and counting of the results was performed as 115 previously described, as was Ki67 staining and counting (11). Counting for BrdU, Ki67 116 and electron microscopy was done by a single examiner blinded to the experimental 117 groups. Hepatic lysates, A1AT protein assays, monomer/polymer assays, caspase blots, 118 electron microscopy, and quantification were carried out as described (1, 11, 12) . 119
Quantitative blots were repeated in triplicate and graphed by scanning as previously 120 published (1, 11, 12) . The following antibodies were used; polyclonal rabbit anti-LC3 121
(1:1000, Cat# NB100-2220, Novus Biologicals), mouse anti-p62 (1:2,500, Cat# 610833, 122 BD Transduction Laboratories), polyclonal rabbit anti-β-tubulin (1:1000, Cat# sc-9104, 123
Santa Cruz), and secondary polyclonal goat anti-rabbit IgG-HRP (1:10,000, Cat# p0448, 124
Dako) and donkey anti-mouse IgG-HRP (1:100,000, Cat# sc-2314, Santa Cruz). β-125 tubulin was used as an invariant control for equal loading. For EM counting of globules 126 with an autophagic vacoule, 25 hepatocytes per liver were examined at random in a 127 masked fashion by a single examiner and the percent globules in membrane continuity 128 with a multilamellar autophagic vacuoles were counted. EM counting of area of 129 cytoplasm occupied by autophagic vacuoles was performed on standard acquired fields, 130 randomly selected, then area of autophagic vacoules counted by overlay grids by a single, 131 masked examiner, as previously published (18, 23 were performed as we previously described using SYBR Green Supermix. mRNA levels 159 are expressed as fold changes after normalization with glyceraldehyde-3-phosphate 160 dehydrogenase (GAPDH), as described(10). The primers for mice used in real-time PCR 161 analyses were shown in Table 1 The profound reduction in mutant Z protein intrahepatic accumulation associated with 281 norUDCA, and the reduction in inflammation, led us to hypothesize that large reductions 282 in other markers of hepatic injury would also be found, consistent with the known 283 intracellular injury cascade associated with A1AT mutant Z protein accumulation (1, 11) . 284
First, we examined serum ALT in the control PiZ mice compared to the norUDCA 285 treated PiZ mice (figure 5a). Past studies have shown an approximate 2-fold increase in 286 ALT in PiZ mice compared to WT mice (WT mouse ALT upper limit of normal in our 287 reference lab is <65 IU/ml), and these data now show reduced ALT to approximately the 288 WT mice level associated with norUDCA treatment (p<0.05)(7). We next examined 289 caspase cleavage since previously published data from many labs have shown that 290 apoptotic signaling via caspase cleavage is associated with intracellular accumulation of 291 mutant Z protein (8, 11, 12, 13, 14, 23) . Caspase 12 in mice is associated with ER stress, 292 such as a burden of unfolded protein in the ER, and caspase 3 is a product cleaved as a 293 late step in the apoptotic cascade. Cleavage of these species indicates increased ER stress 294 apoptotic signaling and increased distal pathway signaling, respectively (10, 16, 23). Our 295 results show reduced caspase 12 cleavage (p=0.01, figure 5b-c) and reduced caspase 3 296 cleavage (p=0.03, figure 5d-e) in PiZ mice treated with norUDCA. Previous work has 297
shown that the caspase cleavage mainly takes place in the small number of cells with the 298 largest mutant Z protein polymer burden (usually the largest globules) and these results 299 are based on whole liver lysates, so while the results are significant, the magnitude of 300 some of the readout may be diluted (11). Several previously published studies have also 301
shown that TUNEL staining in PiZ liver is not useful, as the apoptotic bodies are cleared 302 very rapidly such that the signal in PiZ mouse liver and in human liver is near the limit of 303 detection (1, 11). 304 305 Next, in a group of 10 PiZ control and treated mice, as per the methods, we measured 306 hepatocellular proliferation by 72h BrdU incorporation prior to sacrifice (16). Previously 307 published worked has established this as a marker for hepatocellular death in this, and in 308 other models (16). The results revealed reduced compensatory proliferation of 309 hepatocytes associated with norUDCA treatment (Figure 5f , p=0.02). We also examined 310 proliferation by a second method using Ki67 staining, which is a marker for proliferative 311 entry into the cell cycle (2, 12, 13). Previous work has shown, in both human liver and in 312
PiZ mouse liver, that Ki67 positive liver cells are increased in PiZ liver compared to WT 313 (2). Therefore, we stained and counted Ki67 in three randomly selected PiZ control mice 314 compared to three norUDCA treated PiZ mice and found a significant reduction in the 315 norUDCA treated consistent with reduced compensatory liver proliferation (p=0.04, 316 figure 5g ). 317
318
The final common pathway of liver cell death and regeneration is liver fibrosis. Fibrosis 319 develops in both the PiZ mouse model and in human A1AT ZZ liver, but in both cases it 320 is usually late in adulthood (2, 3, 9, 10, 13). In PiZ mice this is seen at about 12mo of age. 321
We examined our young adult mice (2 mo of age) treated with norUDCA for excess 322 fibrosis compared to controls (figure 5h) and found that no excessive fibrosis above 323
normal had yet developed in the control mice, and that this was not different from the 324 norUDCA treated mice. to deal with the toxic accumulation. The ubiquitin-proteasome system, termed "ER-338 associated degradation" (ERAD) is the primary route of disposal for newly synthesized, 339 but abnormally folded, mutant Z protein monomers (1, 8, 11). Autophagic degradation is 340 important in degrading the large, and often insoluble mutant Z protein polymer, both in 341 non-dilated ER and within the globules (8, 9). Autophagy is a highly conserved 342 intracellular process of mass disposal within unique vacuoles. For these reasons, we 343 hypothesized that norUDCA was inducing increased autophagic degradation of A1AT 344 mutant Z protein in the PiZ liver as the mechanism of the observed effects. To examine 345 this, we first performed quantification by electron microscopy, as previously described 346 and validated, of the autophagic vacuoles in the control PiZ mice compared to the 347 norUDCA treated PiZ mice (10, 18, 19, 23 figure 6a and 6b) . Next, we confirmed this result of increased autophagic activity 353 associated with norUDCA with a second validated technique to quantify autophagy using 354 LC3 conversion (Figure 6c ). LC3 is a component of the autophagic vacuole membrane 355 and conversion to the species LC3 II is directly related to increased numbers of 356 autophagic vacuoles (9). The results show increased LC3 II in PiZ liver at baseline 357 compared to WT mouse liver at baseline as previously reported, which is further 358 increased in PiZ liver with norUDCA. In preliminary dose-response experiments, the 359 amount of A1AT mutant Z protein in the liver affected the degree of autophagy 360 associated with norUDCA administration. When mice treated for short periods of time (1 361 week) were compared to mice treated until the majority of A1AT was no longer present 362 in the liver (9 weeks), but with the same dose of norUDCA, the autophagic activity was 363 reduced when the A1AT intracellular protein burden was reduced. The more A1AT 364 accumulated in the liver the more sensitive the liver was to increased autophagy 365 associated with norUDCA. Finally, we examined the effect of norUDCA in WT mice and 366 found that there was less increase in LC3 II in WT liver associated with norUDCA. 367
368
In the liver, increased signaling for autophagy is sometime associated with reduced levels 369 of p62, depending on the autophagy activation pathway involved. Therefore, we also 370 examined immunoblots for the mice above (figure 6c) for p62. The results showed no 371 decrease in p62 protein in WT mice associated with norUDCA, but there was a drop in 372 p62 in PiZ mice associated with norUDCA. These data might indicate norUDCA was not 373 acting via a p62 autophagy mechanism or that there was once again, evidence for a 374 different response to norUDCA in WT mice versus PiZ mice. To further explore this 375 question, we examined expression of a variety of genes known to be involved in 376 autophagy ( figure 6d, e, f) . The ATG family of genes encodes proteins which are 377 involved in the signaling and formation of the autophagic vacuoles. Beclin1 is part of the 378 ATG family of autophagic regulation. Gabarap is GABAA-receptor associated protein, 379
and is involved in vacuole formation and regulation by binding to ATG8 and other 380 molecules. Dram1 is known to be involved in some branches of the autophagic activation 381 pathway by interacting with p62. The results of RT PCR quantification of mRNA for 382 these genes revealed significant changes consistent with increased autophagic activity in 383
PiZ liver at baseline compared to WT at baseline (figure 6d), without the presence of 384 norUDCA. When norUDCA treated WT liver was examined (figure 6e), only trends in 385 these genes' expression consistent with autophagic activation were seen without 386 statistical significance. These data call into question the role of norUDCA in autophagic 387 activation in healthy liver. However, in the PiZ mice treated with norUDCA 5 of the 7 388 genes had significant (p<0.05) changes in expression consistent with autophagic 389 activation, including p62 reduced expression consistent with the drop in p62 protein, only 390 seen in the PiZ liver. Together, these data suggest induction of autophagy by norUDCA 391 that is uniquely seen in the presence of mutant Z protein accumulation. 392 393 Our previous work, confirmed by other investigators, has revealed that A1AT mutant Z 394 protein accumulated in the liver in the polymerized conformation is degraded by 395 autophagy and that administration of autophagy enhancers is associated with increased 396 A1AT degradation and a reduced hepatic A1AT burden. We previously detected A1AT 397 within autophagic vacuoles (18, 19, 23) . In this study, we further examined the 398 any change in Z mutant protein liver content, and these dosing schemes do not appear 432 feasible in humans. In our current study, we examined the effect of norUDCA in the PiZ 433 mouse. Our results revealed a strikingly large reduction in the accumulated mutant Z 434 protein in the liver. This was accompanied by large reductions in many of the well-435 known markers of liver injury in this disease. We proposed that we had discovered 436 another autophagy-inducing compound and further study has shown that this is the likely 437 mechanism. This is a novel example of exogenous bile acids inducing autophagy in a 438 way that might be more tolerable as a human therapeutic. 439 440 However, the results are interesting for another aspect of the findings, which is that the 441 effects were only significantly powerful in the PiZ liver and not WT liver. Evidence of 442 autophagic activation associated with norUDCA was abundant in PiZ liver, but in many 443 ways lacking when WT mouse liver was examined, including change in p62. These data 444 could be interpreted to question the hypothesis that norUDCA activates autophagy, but 445 might more likely suggest that the autophagic activation of norUDCA is specific to a 446 cellular environment in which there is already another active degradation signal. In the 447 A1AT literature there are other examples of altered intracellular stress pathways and 448 altered responses to agents which act in these pathways, in cells with a burden of mutant 449 Z protein compared to those without (14, 17, 19) . Some studies suggest a "cocked 450 hammer" mechanism in which a pathway in a cell accumulating mutant Z protein is more 451 easily activated than in an unburdened cell, but signals are not being transduced, yet. It is 452 possible that this is the case here. NorUDCA may be a weak activator of autophagy, 453 unless the autophagic pathway is already upregulated to deal with a burden of mutant 454 protein, and then the response to norUDCA is more pronounced. This feature might make 455 norUDCA even more attractive as a drug treatment. We are pursuing further studies in 456 this, and in other model systems to determine the exact mechanism by which norUDCA 457 activates autophagy and how this is different in cells burdened with mutant Z protein. Other studies of autophagy enhancers have not shown reduced secretion, which was 488 thought to be explained by the hypothesis that polymerization and the degradation of 489 polymer was a trafficking step very much distal to the step of biogenesis which regulates 490 secretion. These data suggest, however, that increased autophagic degradation might not 491 only capture mutant Z protein polymers, but perhaps also newly synthesized monomers 492 which then get degraded rather than secreted. Another possibility is that norUDCA has 493 other, as yet unidentified, effects on trafficking or protein degradation activities which 494 results in reduced cellular export. Guo, S., Booten, S. L., Aghajan, M., Hung, G., Zhao, C., Blomenkamp, K., . . . Haddock, C. J., Blomenkamp, K., Gautam, M., James, J., Mielcarska, J., Gogol, 534 E., . . . Skowyra, D. (2014) . PiZ mouse liver accumulates polyubiquitin 535 conjugates that associate with catalytically active 26S proteasomes.PLoS One, 536 9(9), e106371. 537
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